Indegene sees tailwinds in the US, expanding in Europe
Subscribe to enjoy similar stories. Bengaluru-based life sciences commercialisation firm Indegene sees significant headroom for growth in the US, its largest market, despite uncertainties around the new Trump regime’s stance on regulatory and pricing issues. Top global pharma companies are doubling down on the use of technology and AI to make processes more agile, which plays to Indegene’s strengths, CEO and co-founder Manish Gupta told Mint in an interview.
“A combination of ageing populations, rising incomes, and the fact that technology is at a stage where multiple options can be thrown in [means] this industry will continue to grow for a very long period of time," Gupta said. A large chunk of Indegene’s revenue (64% as of Q3FY25) comes from the top 20 global pharma companies. Most of these are based in the US and Europe, which account for over 95% of the company’s business.
Read more: No negative margin impact from Trump pausing Inflation Reduction Act spending: Waaree's Amit Paithankar Besides leveraging its AI expertise to grow in the US, Indegene is also expanding its footprint in Europe, with a slew of investments and centres in the last few months. Indegene offers commercial services to big pharma to market and sell their products and backend operations like regulatory submissions and data management. The Biden administration’s Inflation Reduction Act in 2022 focused on lowering prescription drug costs, increasing pricing pressure on US biopharma companies.
The current administration has not yet stated its stance on this, but the industry is closely monitoring it. “We have a practice around essentially pricing and market access in the US…that's a very important area for us and pharma companies. That practice of
. Read on livemint.com